New injection for anemia in dialysis patients taking roxadustat
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests a new once-monthly injection called pegmolesatide for anemia in people with kidney disease on dialysis who are already taking roxadustat. It aims to see if switching to this injection can keep hemoglobin levels stable and reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You are on dialysis (peritoneal or hemodialysis) for at least 12 weeks and plan to stay on it.
- You are currently taking roxadustat (a pill for anemia) at a stable dose of 360 mg or less per week.
- Your hemoglobin (red blood cell level) is between 8.0 and 12.0 g/dL, and your iron levels are adequate.
- You have not had a blood transfusion in the last 12 weeks, and you are not using ESAs (injections) together with roxadustat.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, pegmolesatide, to treat anemia in people who have been on dialysis for at least three months. It aims to help improve red blood cell levels without needing as many other anemia treatments.
This trial tests whether starting enarodustat (a pill) at different doses can raise red blood cell levels and treat anemia in people with moderate-to-severe chronic kidney disease who are not yet on dialysis.
This trial tests two different doses of pegmolesatide to treat anemia in people with chronic kidney disease who are not on dialysis. It aims to find which dose works better to raise red blood cell levels.
This trial is for people with heart failure, chronic kidney disease, and low red blood cell counts (anemia). It examines how well the drug roxadustat helps over a long period by looking at medical records from people who have already taken it for more than a year.
This trial tests whether roxadustat can improve kidney oxygen levels and anemia in people with diabetic kidney disease. It may help if you have anemia from kidney problems and are being considered for medicines like erythropoietin (EPO).
This trial tests an investigational drug called roxadustat to see if it can help people with a certain type of low-risk MDS who need frequent red blood cell transfusions. It's for patients who haven't responded to other anemia treatments.
Hear when a new Renal Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.